The associations of incretin hormone concentration with gestational diabetes mellitus

por Tatiana V. Saprina, Ekaterina S. Timokhina, Olga K. Goncharevich, Svetlana V. Budeeva, Tatiana S. Prokhorenko, Lyubov A. Tashireva, Nadezhda N. Musina, Irina V. Dronova
Publicado 2016

Incretins today: multiple effects and therapeutic potential

por Oksana V. Tsygankova, Varvara V. Veretyuk, Alexander S. Ametov
Publicado 2019

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

por Howell R, Wright AM, Clements JN
Publicado 2019

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.

por Ekaterina Alekseevna Shestakova
Publicado 2011

Involvement of the Catecholamine in Glucagon-Induced Thermogenesis in Duckling (Carina Moschata)

por M. Slimani, S. El Antri, S.Lazar, H. Barré, Mostafa Khouili, T. Fechtali
Publicado 2007

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

por Gagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovich
Publicado 2017

Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus

por Ojha A, Ojha U, Mohammed R, Chandrashekar A, Ojha H
Publicado 2019

Effects of exogenous α-(1,4)-amylase on the utilisation of corn starch and glucose metabolism in broiler chickens

por H. Zhou, Y. Wu, X. Sun, D. Yin, Y. Wang, T. Mahmood, J. Yuan
Publicado 2021

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide

por Alexander Sergeevich Ametov, Lyudmila Leonidovna Kamynina
Publicado 2011

Mathematical modelling of root causes of hyperglycemia and hypoglycemia in a diabetes mellitus patient

por Paul S. Mwita, Nyimvua Shaban, Isambi S. Mbalawata, Mary Mayige
Publicado 2021

Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?

por Khoury Johad, Andrawus Elias, Bishop Boaz Y., Azzam Zaher S.
Publicado 2018

Detection of Secondary Metabolites as Biomarkers for the Early Diagnosis and Prevention of Type 2 Diabetes

por Al-Aama JY, Al Mahdi HB, Salama MA, Bakur KH, Alhozali A, Mosli HH, Bahijri SM, Bahieldin A, Willmitzer L, Edris S
Publicado 2019

Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus

por Hua-Xing Huang, Liang-Lan Shen, Hai-Yan Huang, Li-Hua Zhao, Feng Xu, Dong-Mei Zhang, Xiu-Lin Zhang, Tong Chen, Xue-Qin Wang, Yan Xie, Jian-Bin Su
Publicado 2021

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

por Pearson S, Kietsiriroje N, Ajjan RA
Publicado 2019

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes

por Nina A. Petunina, Milena Е. Telnova
Publicado 2018

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus

por Marina Vladimirovna Shestakova
Publicado 2010

Elevated Glucagon-like Peptide-1 and a Th2 Shift May Support Reduced Prevalence of Thoracic Aortic Aneurysm in Patients with Diabetes

por Stelia Ntika, Harshitha Jois, Karin Lång, Christian Olsson, Anders Franco-Cereceda, Hanna M. Björck, Camilla Krizhanovskii
Publicado 2021

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

por Knop FK, Hansen K, Knop FK
Publicado 2010

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day

por Igor A. Sklyanik, Marina V. Shestakova
Publicado 2021

Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats

por A Pegah, I Khodadadi, F Mirzaei, H Tayebinia, E Abbasi
Publicado 2021